|
Synonyms: ADS-001 | ADS001 | ARO-AAT
Compound class:
Nucleic acid
Comment: Fazirsiran (ADS-001) is a small interfering RNA (siRNA) that is designed to target the mRNA that would otherwise be translated into a mutant, misfolded and aggregating version of the AAT protein (known as Z-AAT which is transcribed from the mutant SERPINA1 PI*ZZ allele) in patients with alpha-1 antitrypsin deficiency [2-4].
To improve pharmacokinetics, the nucleotides are chemically modified (2'-O-methyl/2'-MOE and 2'-deoxy-2'-fluoro/2'-F monomers), with a mixed phosphorothioate/phosphate backbone, and it has sugar modifications at both ends of the forward strand to enhance hepatic delivery via binding to liver-expressed asialoglycoprotein receptors (ASGRs). |
| No information available. |
Summary of Clinical Use ![]() |
| Fazirsiran (ADS-001, ARO-AAT) was progressed as a clinical candidate to evelaute its potential to treat alpha-1-antitrypsin deficiency. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT05677971 | Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein | Phase 3 Interventional | Takeda | ||
| NCT06165341 | Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis) | Phase 3 Interventional | Takeda | ||
| NCT03945292 | Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT) | Phase 2 Interventional | Arrowhead Pharmaceuticals | The SEQUOIA study | 1 |